| Name | Title | Contact Details |
|---|
Throughout our 100 plus year history, Hartig Drug has played a key role in progressive retail practices. Did you know that Hartig Drug opened the first self-service drug store in Iowa and was one of the first pharmacies to employ female pharmacists and store managers? The principles upon which A.J. Hartig founded the company, offering the best product selection and providing fanatical service to his customers, are the corner stone of our company culture today. Hartig Drug has expanded its product offerings in retail and pharmacy and has grown via the addition of many stores throughout the years. Our drug stores and pharmacies are located in communities in Northeast Iowa, Northwest Illinois, and Southwest Wisconsin. Hartig Drug operates retail stores, long-term care pharmacies, and Finley Hartig Homecare, a durable medical equipment company. Additionally, we provide pharmacy services to and for several community critical access hospitals and operate MedOne Healthcare, a pharmacy benefit management company that offers customized prescription benefit plans to businesses, prescription discount programs, prescription mail order service and specialty pharmacy services. Hartig Drug remains active in the communities in which we serve. Our employees, live, work and play in the communities in which we operate. This connection to the community is what drives us every day to provide the best possible service and products to our patients and customers. They are our neighbors. At Hartig Drug, we cherish the faith and trust patients and customers have placed in our brand and the way the Hartig name has become synonymous with value, caring associates and a wide selection of quality merchandise.
Galderma Canada Inc. is a Thornhill, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
606018 F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.
Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.